2013 - Fellow of the American Association for the Advancement of Science (AAAS)
His primary areas of study are Nicotine, Nicotinic agonist, Neuroscience, Cognition and Internal medicine. His studies in Nicotinic agonist integrate themes in fields like Anesthesia, Stimulation and Disease. His Neuroscience study incorporates themes from Alzheimer's disease and Physical medicine and rehabilitation.
His Cognition research includes themes of Parkinson's disease and Attention deficit hyperactivity disorder. The concepts of his Internal medicine study are interwoven with issues in Placebo, Endocrinology and Psychiatry. His Endocrinology research is multidisciplinary, relying on both Anxiety, Dementia and Mood.
His main research concerns Cognition, Internal medicine, Neuroscience, Clinical psychology and Endocrinology. His research integrates issues of Menopause, Disease and Mood in his study of Cognition. His research in Internal medicine intersects with topics in Placebo and Depression.
He has researched Neuroscience in several fields, including Alzheimer's disease, Muscarinic acetylcholine receptor and Nicotinic agonist. He has included themes like Stimulation, Pharmacology and Nicotine in his Nicotinic agonist study. His Endocrinology research incorporates themes from Anticholinergic and Anxiety.
Paul A. Newhouse mostly deals with Cognition, Neuroscience, Cognitive decline, Clinical psychology and Effects of sleep deprivation on cognitive performance. Paul A. Newhouse combines subjects such as Placebo, Internal medicine, Menopause, Disease and Neuroimaging with his study of Cognition. His Internal medicine research is multidisciplinary, incorporating elements of Oncology and Cardiology.
His study in the fields of Basal forebrain and Cholinergic under the domain of Neuroscience overlaps with other disciplines such as In vivo. The Cognitive decline study combines topics in areas such as Postmenopausal women, Estrogen and Neuropsychology. His research in Mood focuses on subjects like Late life depression, which are connected to Nicotine.
Cognition, Neuroscience, Nicotinic agonist, Major depressive disorder and Nicotine are his primary areas of study. His Cognition research is multidisciplinary, incorporating perspectives in Audiology and Internal medicine, Menopause, Disease, Estrogen. His study on Disease also encompasses disciplines like
His biological study spans a wide range of topics, including Glutamate receptor, Dysfunctional family and MEDLINE. His Nicotinic agonist research incorporates elements of Clinical trial, Oncology, Quality of life, Ovarian cancer and Breast cancer. His Nicotine study combines topics in areas such as Immunology and Pneumonia.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Clock drawing in Alzheimer's disease. A novel measure of dementia severity.
Trey Sunderland;James L. Hill;Alan M. Mellow;Brian A. Lawlor.
Journal of the American Geriatrics Society (1989)
Effects of nicotinic stimulation on cognitive performance
Paul A Newhouse;Alexandra Potter;Abhay Singh.
Current Opinion in Pharmacology (2004)
Intravenous nicotine in Alzheimer's disease: a pilot study
P. A. Newhouse;T. Sunderland;P. N. Tariot;C. L. Blumhardt.
Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.
Paul A. Newhouse;Alexandra Potter;Edward D. Levin.
Drugs & Aging (1997)
L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition.
Pierre N. Tariot;Robert M. Cohen;Trey Sunderland;Paul A. Newhouse.
Archives of General Psychiatry (1987)
Cognitive-behavioral therapy increases prefrontal cortex gray matter in patients with chronic pain.
David A. Seminowicz;Marina Shpaner;Michael L. Keaser;G. Michael Krauthamer.
The Journal of Pain (2013)
The effects of nicotine on Parkinson's disease
M C Kelton;H J Kahn;C L Conrath;P A Newhouse.
Brain and Cognition (2000)
Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder
Alexandra S. Potter;Paul A. Newhouse.
A new scale for the assessment of depressed mood in demented patients.
Sunderland T;Alterman Is;Yount D;Hill Jl.
American Journal of Psychiatry (1988)
Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease.
Alexandra Potter;June Corwin;Jason Lang;Melissa Piasecki.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: